4. PPH
Traditional definition
Blood loss ≥
500mL following VD, or
1000mL following CS.
(ACOG, 2006)
An updated definition
Cumulative blood loss≥
1000 mL OR
accompanied by SorS of hypovolemia within 24 h
after the birth process regardless of the route of
delivery.
(ACOG, 2017)
Any blood loss sufficient to compromise haemodynamic stability.
ABOUBAKR ELNASHAR
5. For normal woman undergoing CS
Blood loss of 1000 mL
Common
Minimal effect on women’s health status.
For woman with severe anemia or CVD undergoing VD
Blood loss of as little as 200mL
may be
life-threatening
need additional intervention.
ABOUBAKR ELNASHAR
7. TA
Mechanism of action
Potent antifibrinolytic agent= Inhibition of fibrinolysis
blocking lysine binding sites on plasminogen
molecules
Inhibits
activation of plasminogen to plasmin.
ability of plasmin to form fibrin degradation
productions
clot breakdown (fibrinolysis):
bleeding is reduced.
(Pacheco. Obstet Gynecol. 2017)
ABOUBAKR ELNASHAR
8. Normally, plasminogen binds with tissue plasminogen activator (tPA) to form plasmin.
This binding degrades fibrin into fibrin degradation products and leads to clot lysis.
TA binds to the lysine binding site on plasminogen. This new conformation blocks
plasmin binding to fibrin. Fibrin strands are not broken, and a clot persists to slow
bleeding.
ABOUBAKR ELNASHAR
9. Rationale TA administration
During delivery, when the placenta separates
Physiologic and haemostatic changes
1. Strong myometrial contractions
2. Increased platelet activity
Massive release of coagulation factors:
increase fibrinolytic activity
Oxytocin administration:
enhances the first mechanism
TA administration
counter the latter: facilitate the haemostatic
process.
ABOUBAKR ELNASHAR
10. Half life: 2 hours
Metabolized by kidney
Routes of administration:
IV
Oral
Topical
The peak of serum levels after IV infusion:
within minutes in nonpregnant patients.
(Jerath et al, 2018)
ABOUBAKR ELNASHAR
11. Widely uses in
O&G
Cardiac surgery
Oral surgery
Liver transplant
Urology
Effective and safe in reduce blood loss in
Menorrhagia
Hysterectomy
Myomectomy.
(Naoulou et al, 2013Topsoee et al, 2014Shaabanet al, 2015)
ABOUBAKR ELNASHAR
12. ABOUBAKR ELNASHAR
Prophylaxis Treatment
Dose 1 g or
10 mg/kg IV
1 g in 10 mL IV over 10 m
2nd dose of 1 g IV if bleeding
continues after 30 m or
restarts within 24 h of
completing the first dose.
(WHO, 2018)
Timing 10 to 20 m before
skin incision OR
At the time of
umbilical cord clamp
{avoid any placental
transfer}
Within 3h of delivery
Dose & timing in management of PHH
13. ABOUBAKR ELNASHAR
Safety and risks
1.Nausea and vomiting.
The most commonly reported adverse effect
2. At higher doses:
Other gastrointestinal
Seizures
These doses are not recommended for obstetrics
Risk of thrombotic tendency, Seizures
Renal complications: Not higher than controls
(Cochrane SR, 2018)
Rarely
when administered before cord clamping
{TA cross the placenta}:
severe adverse neonatal effects
14. ABOUBAKR ELNASHAR
Contraindications
1. Known hypersensitivity to TA
2. Significant renal impairment.
3. Active thrombotic disease:
DVT, pulmonary embolism, and cerebral thrombosis.
4. Significant history or risk for VTE
unless it is possible to simultaneously administer anticoagulation.
5. Rare contraindications:
disturbances of color vision before or during administration of TXA
or
active subarachnoid hemorrhage
15. ABOUBAKR ELNASHAR
Cost-effectiveness
highly cost-effective in low- to middle-income
countries
equally cost-effective in other countries with a high
burden of maternal mortality due to PPH.
(Li et al, 2018)
18. WOMAN trial
20,060 woman with diagnosed PPH
193 hospitals in 21 countries
Significant decrease in death due to bleeding
Hysterectomy rates did not change
Death from all causes did not decrease
No increase in adverse outcomes with TA
( VTE)
Effects of early tranexamic acid administration on mortality, hysterectomy, and
other morbidities in women with postpartum hemorrhage (WOMAN):
An international, randomized, double-blind, placebo controlled trial.
Lancet , 2017
ABOUBAKR ELNASHAR
21. WHO recommendation, 2017
Early use(within 3 h of birth) of IV TA
in addition to standard care
is recommended for women with clinically
diagnosed PPH following
vaginal birth or
CS.
(Strong recommendation, moderate quality of evidence)
TA administration beyond 3 h
does not confer any clinical benefit
harm, albeit not statistically significant for women with PPH.
No support for use of TA more than 3 h after birth.
ABOUBAKR ELNASHAR
22. TA should be used in all cases of PPH
regardless of whether the bleeding is due to
genital tract trauma or
other causes.
The use of TA should be avoided in
clear contraindication to antifibrinolytic therapy
known thromboembolic event during pregnancy
ABOUBAKR ELNASHAR
23. Cochrane SR, 2018
IV TA
reduces mortality due to bleeding in women with
primary PPH
irrespective of mode of birth
without increasing the risk of thromboembolic
events
effective if given as early as possible.
Alternative routes to IV administration need to be
investigated
ABOUBAKR ELNASHAR
24. 3. TA FOR PREVENTION OF PPH
I. According to route of delivery
II. According to risk for PPH
ABOUBAKR ELNASHAR
25. ABOUBAKR ELNASHAR
I. According to Route of delivery
A. Prophylactic TA in vaginal delivery
TRAAP trial 2018
(Sentilhes et al, 2018)
Tranexamic Acid for the Prevention of Postpartum
Hemorrhage After Vaginal Delivery
Multicenter, double-blind, RCT
4,070 singleton gestations ≥35 w
1 g within 2 min after vaginal delivery
Lower incidence of PPH
(6.6% vs 8.8%, P = 0.01),
reduced need for uterotonics
(7.3% vs 9.7%, P =0.003)
26. ABOUBAKR ELNASHAR
Prophylactic TA cannot be routinely recommended in
vaginal delivery
1. In spite of statistically significant decrease in blood
loss
this may not convey clinical significance in terms of
transfusion rates and
maternal comorbidity from severe hemorrhage.
2. Limited high-quality evidence
Larger, well designed RCTs are required to help
formulate guideline recommendations.
27. ABOUBAKR ELNASHAR
B. Prophylactic TA in CS
Wang et al 2015
11 RCTs
before elective CS
TXA intervention significantly reduced
intraoperative blood loss during and after cesarean
delivery
without an increase in thromboembolic events;
reduction was similar for both 1 g dosing and
weight-based TXA dosing regimens.
28. ABOUBAKR ELNASHAR
Simonazzi et al, 2016
9 RCT, 2365 CS, including multiple pregnancies,
elective and selective CS
TA compared with controls. had significantly less
Blood loss
(−160.27; 95% CI, −224.63 to−95.92)
Drop in hemoglobin
(−0.61 g/dL;95% CI, −1.04 to −0.18)
PPH
Need for uterotonics
(4.2% vs 7.3%; RR, 0.54; 95% CI,0.36–0.81).
Blood transfusion
(1.9% vs 5.7%; RR, 0.33; 95% CI, 0.19–0.58).
Heterogeneity in
TA dosing & timing
Methods for measuring blood loss
29. Li et al, 2017 SR
25 articles
4747 participants
TA
Reduced blood loss
ABOUBAKR ELNASHAR
TotalPostoperativeIntra operative
155 ml36 ml140 mlCS
85 ml41ml23 mlVD
Lower rate of
PPH
Blood transfusions.
No increased risk of DVT
Minor side effects were more common
30. ABOUBAKR ELNASHAR
II. According to risk of PPH
In the prevention of PPH TA should be considered in
addition to oxytocin
At the time of CS in women who are at risk for
PPH
(RCOG Green -top Guideline, 2016)
Before both vaginal and CS in patients at higher
risk for PPH
(Ahmadzia et al, 2018)
Prediction of PPH is based mostly on clinical risk
factors.
(James et al, 2012)
33. ABOUBAKR ELNASHAR
CONCLUSIONS
In the treatment of PPH
1 g of IV TA should be initiated within 3 h of birth
In prevention of PPH
1g of IV TA after cord clamping of both vaginal and
CD should be considered in patients at higher risk
for PPH.
34. ABOUBAKR ELNASHAR
You can get this lecture and 404 lectures
from:
1.My scientific page on Face book:
Aboubakr Elnashar Lectures.
https://www.facebook.com/groups/2277
44884091351/
2.Slide share web site
3. elnashar53@hotmail.com
4. My clinic, 3 Althawra St. Almansura